UroGen Pharma
URGN
64 hedge funds and large institutions have $115M invested in UroGen Pharma in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 5 closing their positions.
31,100% more call options, than puts
Call options by funds: $1.25M | Put options by funds: $4K
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
7% more funds holding
Funds holding: 60 → 64 (+4)
4% more capital invested
Capital invested by funds: $111M → $115M (+$4.63M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.18% less ownership
Funds ownership: 58.58% → 56.4% (-2.2%)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.71M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$863K |
| 3 |
Citigroup
New York
|
+$514K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$369K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.97M |
| 2 |
Millennium Management
New York
|
-$1.54M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$803K |
| 4 |
JP Morgan Chase
New York
|
-$492K |
| 5 |
E
Ergoteles
New York
|
-$406K |
URGN Hedge Fund Activity: Q4 2022 in Review
64 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2022, worth a combined $115M — up 4.2% from $111M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new URGN positions and 5 closed out — a net gain of 5 holders — while 14 added to existing stakes and 19 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $1.71M. The largest seller was Great Point Partners, cutting an estimated $2.97M.
- 64 institutional investors held UroGen Pharma (URGN) as of Q4 2022, up from 60 in Q3 2022.
- Funds reported $115M of UroGen Pharma stock for Q4 2022, up 4.2% quarter-over-quarter.
- 10 funds opened new UroGen Pharma positions in Q4 2022 and 5 closed out, a net change of +5 holders.
- The largest UroGen Pharma buyer in Q4 2022 was Stonepine Capital Management, an estimated $1.71M added.
- The largest UroGen Pharma seller in Q4 2022 was Great Point Partners, an estimated $2.97M sold.
Based on aggregated 13F filings for Q4 2022.